Abiomed provides temporary percutaneous mechanical circulatory support devices and offers a continuum of care to heart failure patients.Read more
Abiomed's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 6B. Over the last four quarters, Abiomed's revenue has grown by 8.3%. Specifically, in Q4 2021's revenue was $261.2M; in Q3 2021, it was $248.1M; in Q2 2021, it was $252.6M; in Q1 2021, Abiomed's revenue was $241.2M.